Askel Healthcare Celebrates Milestone Achievement: Patent Granted for Innovative Knee Cartilage Repair Technology

FOR IMMEDIATE RELEASE                                                                                                                                                        12.04.2024

Askel Healthcare Celebrates Milestone Achievement: Patent Granted for Innovative Knee Cartilage Repair Technology

[Helsinki, Finland] – Askel Healthcare proudly announces the issuance of its first patent for cutting-edge technology designed to address knee cartilage defects. This significant milestone marks a pivotal moment in the company’s journey towards revolutionizing the care of focal cartilage defects.

The granted patent encompasses Askel Healthcare’s pioneering solution for repairing knee cartilage defects, a crucial advancement in the field of orthopedics. Leveraging years of research and development, the patented technology behind COPLA® Cartilage implant, promises to redefine treatment options for patients suffering from painful knee cartilage injuries.

With a strategic vision towards global expansion, Askel Healthcare has strategically pursued patent protection across multiple jurisdictions. In addition to securing unitary effect under the Unitary Patent system, which covers 17 European countries, the company has also extended its patent coverage to key markets including the United Kingdom, Spain, and Switzerland. This comprehensive approach ensures that Askel Healthcare’s innovative technology is safeguarded in a total of 20 countries in Europe, laying a solid foundation for international growth and market penetration.

Dr. Anne-Marie Haaparanta, Chief Technology Officer and co-founder of Askel Healthcare, expressed her excitement about this milestone achievement, stating, “This is a major milestone for us. Having our technology patented is something we have long waited for. Our technology is the key, and in-house manufacturing on top of it makes our core, the technology behind COPLA®, so much stronger.”

Looking ahead, Askel Healthcare remains committed to furthering its global footprint and enhancing patient care. The company’s technology has pending patent applications in multiple jurisdictions, including the United States and China, reflecting its dedication to securing broad patent coverage for its groundbreaking innovations.

Askel Healthcare’s unwavering commitment to innovation and excellence continues to drive advancements in orthopedic healthcare, offering hope and healing to patients worldwide.

For media inquiries, please contact:

CTO, Anne-Marie Haaparanta

am.haaparanta@askelhealthcare.com

Previous Post
Askel Healthcare Ltd Announces Strategic Board Appointments and New Chairman
Next Post
Askel Healthcare to Present First Clinical Trial Results of Its COPLA® Knee Cartilage Implant at the 9th Joint Preservation Congress in Warsaw, Poland on June 14-15, 2024